Bosentan therapy for portopulmonary hypertension

Bosentan Therapy for Pulmonary Arterial Hypertension

2002 • 2,715 citations

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study

2001 • 1,521 citations

Pulmonary-Hepatic vascular Disorders (PHD)

2004 • 772 citations

The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions

2001 • 490 citations

Pulmonary hypertension complicating portal hypertension: Prevalence and relation to splanchnic hemodynamics

1991 • 489 citations

Portopulmonary hypertension and hepatopulmonary syndrome

2004 • 488 citations

Pulmonary vascular disorders in portal hypertension

1998 • 360 citations

Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension

2003 • 352 citations

Primary Pulmonary Hypertension and Cirrhosis: Are They Related?^1–3

1983 • 316 citations

Association between primary pulmonary hypertension and portal hypertension: Analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations

1991 • 305 citations

Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension

1999 • 288 citations

Frequency and Clinical Implications of Increased Pulmonary Artery Pressures in Liver Transplant Patients

1996 • 269 citations

CONTINUOUS INTRAVENOUS INFUSION OF EPOPROSTENOL FOR THE TREATMENT OF PORTOPULMONARY HYPERTENSION1

1997 • 241 citations

Compassionate Use of Continuous Prostacyclin in the Management of Secondary Pulmonary Hypertension: A Case Series

1999 • 219 citations

Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids

2003 • 206 citations

Hemodynamic Effects of Bosentan, an Endothelin Receptor Antagonist, in Patients With Pulmonary Hypertension

2000 • 185 citations

Portopulmonary hypertension in decompensated cirrhosis with refractory ascites

2003 • 182 citations

PORTOPULMONARY HYPERTENSION AND THE LIVER TRANSPLANT CANDIDATE

1999 • 136 citations

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study

2002 • 134 citations

SUCCESSFUL USE OF CHRONIC EPOPROSTENOL AS A BRIDGE TO LIVER TRANSPLANTATION IN SEVERE PORTOPULMONARY HYPERTENSION1

1998 • 129 citations

Hepatopulmonary syndrome and portopulmonary hypertension

2003 • 114 citations

Moderate Primary Pulmonary Hypertension in Patients Undergoing Liver Transplantation

1996 • 83 citations

Moderate Primary Pulmonary Hypertension in Patients Undergoing Liver Transplantation

1996 • 76 citations

Endothelin-1 plays a major role in portal hypertension of biliary cirrhotic rats through endothelin receptor subtype B together with subtype A in vivo

2001 • 63 citations

Successful liver transplantation in patients with mild to moderate pulmonary hypertension.

1993 • 56 citations

Endothelin-1 induces vasoconstriction on portal-systemic collaterals of portal hypertensive rats

2001 • 48 citations

Overexpression of endothelin-1 in bile duct ligated rats: correlation with activation of hepatic stellate cells and portal pressure

2001 • 44 citations

Influence of Mild Liver Impairment on the Pharmacokinetics and Metabolism of Bosentan, a Dual Endothelin Receptor Antagonist

2003 • 39 citations

Plasma endothelin-1 levels in patients with biliary atresia: possible role in development of portal hypertension

2003 • 15 citations

Plasma Endothelin-1 Concentrations in Children With Cirrhosis and Their Relationship to Renal Function and the Severity of Portal Hypertension

2002 • 11 citations

Activity of aminopeptidase M, dipeptidylpeptidase IV and g-glutamyltransferase in the gallbladder mucosa of donors for organ transplantation

2001 • 2 citations